Clinical Trial Update: Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adaptive de-escalation of therapy for favorable-risk HPV-positive oropharyngeal cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-associated Oropharyngeal Cancer
• Oropharyngeal Cancer

Snippet

Sponsor: NYU Langone Health | Conditions: Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING